Literature DB >> 32924059

The Natural History of SARS-Cov-2 Related Multisystem Inflammatory Syndrome in Children (MIS-C): A Systematic Review.

Stephen C Aronoff1,2, Ashleigh Hall1, Michael T Del Vecchio1,2.   

Abstract

BACKGROUND: The clinical manifestations and natural history of severe acute respiratory distress syndrome coronavirus 2 (SARS-Cov-2) related Multisystem Inflammatory Syndrome in Children (MIS-C) are poorly defined. Using a systematic review of individual cases and case series and collating elements of the clinical course, the objective of this study was to provide a detailed clinical description and natural history of MIS-C.
METHODS: Case reports and series of MIS-C were recovered from repeated MEDLINE searches, a single EMBASE search and table of contents reviews of major general medicine and pediatric journals performed between June 3 and July 23, 2020. Fever, evidence of inflammation, and evidence of organ dysfunction were required for inclusion.
RESULTS: MEDLINE and EMBASE searches produced 129 articles and 10 articles were identified from journal contents or article bibliographies; 16 reports describing 505 children with MIS-C comprise this review. Thirty- two children (14.7%) had negative results for SARS-Cov-2 by nucleic acid and/or antibody testing. The weighted median age was 9 years (6 months to 20 years). Clinical findings included fever (100%), gastrointestinal symptoms (88.0%), rash (59.2%), conjunctivitis (50.0%), chelitis/ "strawberry tongue" (55.7%) or extremity edema/erythema (47.5%). Median serum CRP, ferritin, fibrinogen and D dimer concentrations were above the normal range. Intravenous gammaglobulin (78.1%) and methylprednisolone/prednisone(57.6%) were the most common therapeutic interventions ; immunomodulation was used in 24.3% of cases. Myocardial dysfunction requiring ionotropic support (57.4%) plus extracorporeal membrane oxygenation (5.3%), respiratory distress requiring mechanical ventilation (26.1%), and acute kidney injury (11.9%) were the major complications; anticoagulation was used commonly (54.4%) but thrombotic events occurred rarely (3.5%). Seven (1.4%) children died.
CONCLUSIONS: MIS-C following SARS-Cov-2 infection frequently presents with gastrointestinal complaints and/or rash; conjunctivitis, chelitis and/or extremity changes also occur frequently. Serious complications occur frequently and respond to aggressive supportive therapy.
© The Author(s) 2020. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  MIS-C; SARS-Cov-2; systematic review

Year:  2020        PMID: 32924059     DOI: 10.1093/jpids/piaa112

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN: 2048-7193            Impact factor:   3.164


  26 in total

1.  The Trilogy of SARS-CoV-2 in Pediatrics (Part 2): Multisystem Inflammatory Syndrome in Children.

Authors:  Van L Tran; Sarah Parsons; Andrew Nuibe
Journal:  J Pediatr Pharmacol Ther       Date:  2021-05-19

2.  Comparison of Multisystem Inflammatory Syndrome in Children-Related Myocarditis, Classic Viral Myocarditis, and COVID-19 Vaccine-Related Myocarditis in Children.

Authors:  Trisha Patel; Michael Kelleman; Zachary West; Andrew Peter; Matthew Dove; Arene Butto; Matthew E Oster
Journal:  J Am Heart Assoc       Date:  2022-04-27       Impact factor: 6.106

3.  [Clinical and radiological findings for the new multisystem inflammatory syndrome in children associated with COVID-19].

Authors:  R Sánchez-Oro; M L Fatahi Bandpey; E García Martínez; M Á Edo Prades; E M Alonso Muñoz
Journal:  Radiologia       Date:  2021-03-11

Review 4.  Immune profiling of COVID-19: preliminary findings and implications for the pandemic.

Authors:  Holden T Maecker
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

5.  Different hair loss patterns in two pediatric patients with COVID-19-associated multisystem inflammatory syndrome in children.

Authors:  Yıldız Hayran; Ahu Yorulmaz; Güneş Gür; Akın Aktaş
Journal:  Dermatol Ther       Date:  2021-02-07       Impact factor: 3.858

6.  SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges.

Authors:  Dan M Cooper; Behnoush Afghani; Carrie L Byington; Coleen K Cunningham; Sidney Golub; Kim D Lu; Shlomit Radom-Aizik; Lainie Friedman Ross; Jasjit Singh; William E Smoyer; Candice Taylor Lucas; Jessica Tunney; Frank Zaldivar; Erlinda R Ulloa
Journal:  Pediatr Res       Date:  2021-02-24       Impact factor: 3.756

Review 7.  Skin disorders associated with the COVID-19 pandemic: A review.

Authors:  Jennifer Akl; Jessica El-Kehdy; Antoine Salloum; Anthony Benedetto; Paula Karam
Journal:  J Cosmet Dermatol       Date:  2021-07-01       Impact factor: 2.189

Review 8.  Clinical features of multisystem inflammatory syndrome in children.

Authors:  Jordan E Roberts; Lauren A Henderson
Journal:  Curr Opin Rheumatol       Date:  2021-09-01       Impact factor: 4.941

9.  Clinical and radiological findings for the new multisystem inflammatory syndrome in children associated with COVID-19.

Authors:  R Sánchez-Oro; M L Fatahi Bandpey; E García Martínez; M Á Edo Prades; E M Alonso Muñoz
Journal:  Radiologia (Engl Ed)       Date:  2021-06-05

Review 10.  Current Understanding of Multisystem Inflammatory Syndrome (MIS-C) Following COVID-19 and Its Distinction from Kawasaki Disease.

Authors:  Hulya Bukulmez
Journal:  Curr Rheumatol Rep       Date:  2021-07-03       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.